- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT04401241
How Routine Biomarkers and Blood Leucocytes Count Can Assist Diagnosis of COVID-19 in Emergency Department (MONACOVID)
Accuracy of Routine Biomarkers and Blood Leucocytes Count to Assist Diagnosis of COVID-19-related Pneumonia in Adult Patients Visiting the Emergency Department
December 2019 was the onset of an outbreak of an infection related to SARS-CoV-2, a new coronavirus detected in January 2020 and responsible for a disorder termed COVID-19. Since then, COVID-19 has spread worldwide and is responsible for an unprecedented pandemic with major threat on global health and social and economic stability.
Covid-19 has a large spectrum of symptoms. Most patients experience mild or moderate flu-like disorder with cough, fever, and shortness of breath. More severe presentations may occur; patients sometimes develop an acute pneumonia that can lead to adult respiratory distress syndrome. A considerable number of publications have been released for the last 10 weeks to help physicians making diagnosis and treat patients. Chinese authors have extensively proposed description of the disease. As signs and symptoms are poorly specific, diagnosis mostly relies on detection of the virus by RT-PCR in the upper respiratory tract. Some uncommon images and localization are highly specific and sensitive on chest CT-scan, which is cornerstone for initial diagnosis. However, resources may lack during healthcare crisis and results of these investigations may be delayed or unavailable developper. Special attention should also be paid to usual laboratory analysis. Indeed, decreased lymphocytes and eosinophilic counts are frequently described as well as increase in D-dimers levels. Variation of C-reactive protein (CRP) and procalcitonin (PCT) have been reported. Coronavirus may have cardiac tropism and changes in cardiac biomarkers concentration may occur. Therefore, some data suggest that values of routine biomarkers and blood cell count may assist physicians at bedside to support diagnosis of COVID-19.
To face the outbreak, organization of emergency departments (ED) was mandatory to separate patients flows and avoid mixing patients with COVID-19 and others. Most patients visiting EDs dedicated to initial COVID-19 management suffered of pneumonia-like symptoms. Despite initial triage, patients had either COVID-19-related pneumonia either alternative diagnoses. We took advantage of this to evaluate the ability of routine biomarkers and leucocytes count helping identification of COVID-19 from alternative diagnoses.
연구 개요
상태
정황
상세 설명
Methods Setting Investigator designed a single center, retrospective, observational study conducted from February 2020 to April 2020 in the emergency department (ED) of Princesse Grace Hospital center, a general hospital in Monaco. The study was monitored by the research department of the Hospital Center. No specific funding was obtained for this study. The institutional review board for the protection of human subjects approved the study protocol and waved the need for written informed consent for inclusion.
Objectives The primary objective was to assess sensitivity of routine biomarkers and blood cell count for diagnosis of COVID-19-related pneumonia in low and high probability groups for level of certainty using the adjudication committee classification.
Secondary objectives were :
- to compare values in the four different categories of level of certainty and between low and high probability groups;
- to assess performance of combined routine biomarkers and blood cell count for diagnosis of COVID-19-related pneumonia;
- to assess whether usual biomarkers and blood cell count were associated with diagnosis of COVID-19-related pneumonia using sensitivity analyses in two predefinite subgroups chosen a priori; Group 1 : when considering patients classified as having low probability and high probability COVID-19-related pneumonia; Group 2 : when patients with excluded COVID-19-related pneumonia and diagnosed extra-pulmonary infectious disease were not taken into account, in the low probability COVID-19-related pneumonia group.
Adjudication committee Based on data collected from baseline on standardized case report forms, results of low dose chest CT-scan, of SARS-Cov-2 specific RT-PCR, and full access to all available data including patients' discharge summary, an adjudication committee consisting of three independent senior experts in infectious diseases, pneumology and radiology retrospectively assigned the probability of COVID-19-related pneumonia diagnosis using the 4-level Likert scale. For this study, the gold standard was the diagnosis assessed by the adjudication committee. Alternative diagnoses were established for low probability COVID-19-related pneumonia and classified as non-COVID pulmonary diseases and extra-pulmonary infectious diseases and others.
A Likert scale allowed distribution of patients in four categories:
- absence of COVID-19-related pneumonia hereafter referred to as excluded;
- possible COVID-19-related pneumonia;
- probable COVID-19-related pneumonia;
- definite COVID-19-related pneumonia. After this first classification, patients were distributed in two groups: low probability COVID-19-related pneumonia (excluded and possible) and high probability COVID-19-related pneumonia (probable and definite).
Study population For the study purpose and to ensure quality of the final adjudication committee diagnosis, investigator selected consecutive adults (18 years of age and above) visiting the COVID-19-dedicated ED if they presented with clinically suspected COVID-19-related pneumonia and had SARS-Cov-2 RT-PCR and/or low dose chest CT-scan.
Patient management and usual biomarkers and blood cell count Patients' management in the COVID-19-dedicated ED was based on local protocoled practices based upon collegial multidisciplinary decision if they presented with suspected COVID-19-related pneumonia. Recorded baseline data consisted of demographic data (age, gender), coexisting illnesses, treatments, symptoms, clinical findings and predetermined laboratory tests including: SARS-Cov-2 specific RT-PCR obtained on nasopharyngeal swab; low-dose chest CT-scan; standard blood analysis (complete blood count, hemostasis, metabolic panel, creatinine, blood urea nitrogen, liver enzymes), D-dimers (Vidas, Biomérieux), procalcitonin, C-reactive protein (CRP), high sensitive cardiac troponin T (cTnT-hs, Cobas, Roche diagnostics), NT-pro-brain natriuretic peptide (NT-proBNP, Cobas, Roche diagnostics). For each individual, CRB65 and Pneumonia Severity Index (PSI) were calculated.
Microbiological samples Naso-pharyngeal swabs were collected at admission and placed in a Middle Virocult MWE (Sigma®) transport medium. Samples were kept at room temperature and sent to the laboratory immediately after collection. For the presence of SARS-COV-2, swabs were sent to French referent centers of virology (Nice, Marseille, Paris). Routine microbiological examinations were also performed at the discretion of the emergency physicians and included : presence of influenza A and B viruses and respiratory syncytial virus (RSV) A and B on nasopharyngeal swabs, blood culture, urine antigens for Streptococcus pneumoniae and Legionella pneumophila type I, serodiagnosis of Mycoplasma pneumoniae. These results were available to the adjudication committee.
Low dose chest CT-scan data and COVID-19-related pneumonia diagnosis classification Multidetector low dose thoracic CT-scan was performed for each individual patient and interpretation was recorded using a standardized report form according to guidelines. The level of COVID-19-related pneumonia probability according to low dose chest CT scan were defined.
Statistical analysis Baseline and follow-up characteristics were described by means and standard deviations (SD) or by median and interquartile range (IQR) for continuous variables with normal or with skewed distribution, respectively, and by percentages for categorical variables. Chi-square or Fisher exact tests were performed when appropriate for qualitative variables. The Student or Mann-Whitney tests were used to compare baseline characteristics and study outcomes between study groups for continuous variables with skewed distributions.
The distribution of values for usual biomarkers and blood cell count were determined in the different populations of patients using boxplots. The performances of current laboratory data in predicting definite COVID-19-related pneumonia were evaluated by sensitivity analysis (definite vs excluded COVID-19-related pneumonia). CRP was evaluated at several cut-off points of 20 mg/L, 30 mg/L, 50 mg/L, 70 mg/L, and 100 mg/L, values used in previous studies. Several cut-off points for PCT were chosen at the level of 0.10 μg/L, and at the two levels for suspected bacterial infection as stated by the manufacturer, i.e., 0.25 μg/L and 0.50 μg/L. Cut-offs for cTnT-hs were 0.014ng/mL and 50ng/mL. Cut-offs for D-dimers test were 500µg/ml and age-adjusted threshold. Sensitivities, specificities, positive predictive values (PPVs), negative predictive values (NPVs), and likelihood ratio were calculated. Receiver operating characteristic (ROC) curves were drawn, area under the curve AUC was computed and optimal cut-off was identified by the maximization of the Youden's index, comparing laboratory results values in patients with excluded COVID-19-related pneumonia and definite COVID-19-related pneumonia. From these optimal cut-offs for laboratory results, sensitivity analyses were performed combining cut-offs.
A multivariate logistic regression model was built to identify factors associated with having definite COVID-19-related pneumonia as compared to having an excluded COVID-19-related pneumonia diagnosis. Investigator excluded from the excluded CAP diagnosis group, patients with an extra-pulmonary infectious disease. All variables with a p value of < 0.25 in the bivariate analysis were entered into a multivariate logistic regression with a backward stepwise approach; the discrimination was evaluated by the C-index and its 95 % confidence interval (95 % CI) and the calibration was evaluated by the Hosmer Lemeshow goodness-of-fit test.
All tests were two-sided, and p-values below 0.05 were considered to denote statistical significance. All statistical analyses were performed using SPSS statistical software version 21.0 (SPSS Inc., Chicago, IL, USA).
연구 유형
등록 (실제)
연락처 및 위치
연구 장소
-
-
MON
-
Monaco, MON, 모나코, 98000
- Centre Hospitalier Princesse Grace
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- patient suspected of COVID19
Exclusion Criteria:
- patient unsuspected of COVID19
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
routine biomarkers and blood cell count are discriminant to diagnose COVID-19
기간: 2 months
|
assess sensitivity of routine biomarkers and blood cell count for diagnosis of COVID-19-related pneumonia in low and high probability groups for level of certainty using the adjudication committee classification
|
2 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Probability of COVID-19 and CRP
기간: 2 months
|
An adjudication committee with full access to medical charts will classify patients in 4 categories for diagnosis of COVID-19 associated pneumonia : certain, probable, unlikely, and excluded.
Patients will be distributed in 2 probability groups : high probability (certain + probable) and compared with low probability patients (unlikely + excluded).
Se, Sp, PPV, NPV, Likelihood ratios will be assessed comparing the 2 groups regarding CRP.
|
2 months
|
Probability of COVID-19 and PCT
기간: 2 months
|
An adjudication committee with full access to medical charts will classify patients in 4 categories for diagnosis of COVID-19 associated pneumonia : certain, probable, unlikely, and excluded.
Patients will be distributed in 2 probability groups : high probability (certain + probable) and compared with low probability patients (unlikely + excluded).
Se, Sp, PPV, NPV, Likelihood ratios will be assessed comparing the 2 groups regarding PCT.
|
2 months
|
Probability of COVID-19 and Ddimers
기간: 2 months
|
An adjudication committee with full access to medical charts will classify patients in 4 categories for diagnosis of COVID-19 associated pneumonia : certain, probable, unlikely, and excluded.
Patients will be distributed in 2 probability groups : high probability (certain + probable) and compared with low probability patients (unlikely + excluded).
Se, Sp, PPV, NPV, Likelihood ratios will be assessed comparing the 2 groups regarding Ddimers.
|
2 months
|
Probability of COVID-19 and NTproBNP
기간: 2 months
|
An adjudication committee with full access to medical charts will classify patients in 4 categories for diagnosis of COVID-19 associated pneumonia : certain, probable, unlikely, and excluded.
Patients will be distributed in 2 probability groups : high probability (certain + probable) and compared with low probability patients (unlikely + excluded).
Se, Sp, PPV, NPV, Likelihood ratios will be assessed comparing the 2 groups regarding NTproBNP.
|
2 months
|
Probability of COVID-19 and cTnT-HS
기간: 2 months
|
An adjudication committee with full access to medical charts will classify patients in 4 categories for diagnosis of COVID-19 associated pneumonia : certain, probable, unlikely, and excluded.
Patients will be distributed in 2 probability groups : high probability (certain + probable) and compared with low probability patients (unlikely + excluded).
Se, Sp, PPV, NPV, Likelihood ratios will be assessed comparing the 2 groups regarding cTnT-HS.
|
2 months
|
Probability of COVID-19 and blood cell counts
기간: 2 months
|
An adjudication committee with full access to medical charts will classify patients in 4 categories for diagnosis of COVID-19 associated pneumonia : certain, probable, unlikely, and excluded.
Patients will be distributed in 2 probability groups : high probability (certain + probable) and compared with low probability patients (unlikely + excluded).
Se, Sp, PPV, NPV, Likelihood ratios will be assessed comparing the 2 groups regarding blood cell counts.
|
2 months
|
performance of combined routine biomarkers
기간: 2 months
|
Assess performance of combined routine biomarkers and blood cell count for diagnosis of COVID-19-related pneumonia independent parameters that will significantly differ in a univariate analysis will be combined.
Their characteristics will be reported (Se, Sp, PPV, NPV, Likelihood ratios).
The above mentioned assessment will be held at the exclusion of others
|
2 months
|
Assess usual biomarkers and blood cell count
기간: 2 months
|
ii) to assess performance of combined routine biomarkers and blood cell count for diagnosis of COVID-19-associated pneumonia; assessment of characteritics for high probability and low probability patients : P value and AUC [95% CI] will be assessed comparing the 2 groups. iii) to assess whether usual biomarkers and blood cell count were associated with diagnosis of COVID-19-associated pneumonia using sensitivity analyses in predefinite subgroups chosen a priori; 1) when comparing definite versus excluded patients; 2) when comparing high vs. low probability patients, excluding bacterial infection (respiratory and extra-respiratory) in the low probability COVID-19-associated pneumonia group; 3) when comparing definite versus excluded probability patients, excluding bacterial infections (respiratory and extra-respiratory) in excluded patients. For each, P value and AUC [95% CI] will be assessed comparing the 2 groups |
2 months
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 20-06
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
코로나19에 대한 임상 시험
-
Texas Woman's UniversityNational Institutes of Health (NIH)아직 모집하지 않음COVID19 테스트
-
Cairo UniversityKasr El Aini Hospital알려지지 않은
-
Assistance Publique - Hôpitaux de Paris알려지지 않은
-
Brugmann University Hospital모병
-
Istituti Clinici Scientifici Maugeri SpAIstituto Auxologico Italiano; Azienda Ospedaliera Bolognini di Seriate Bergamo; Azienda Socio... 그리고 다른 협력자들완전한
-
Abderrahmane Mami HospitalDacima Consulting; Eshmoun Clinical Research Center빼는
-
Aarhus University HospitalUniversity of Aarhus; Pharma Nord완전한